Gabinet Lekarski Malgorzata Saryusz-Wolska
Lodz 90-132
2 studies enrolling now · 9 studies all time
What they study most
Cardiovascular Disease, Chronic Kidney Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Obesity, Overweight, Type 2 Diabetes, Type 2 Diabetes Mellitus
Studies at this site
- A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes — Recruiting now
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels — Running, not enrolling
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before — Completed
- A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) — Completed
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo — Completed
- AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Starting soon
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) — Completed
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes — Completed
- Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) — Completed